Additional Information
Juan Bustillo, M.D.
Professor of Psychiatry and Neurosciences Director, Schizophrenia Research Program Medical Director Spanish Speaking Clinic Attending Psychiatrist, Clozapine Clinic Research Mentor NIH, Scientific Review Group ITVA (Interventions Committee for Adult Disorders). Member: 6/2011 to 2/2014 Exemplary Psychiatrist Award, National Alliance on Mental Illness, 2008 Member of the Task Force (Psychotic Disorders Work Group) for the Diagnostic and Statistical Manual of Mental Disorders- Fifth Edition (DSM-5). American Psychiatric Association, 2007-2013 Statement:
I am interested in the understanding and treatment of schizophrenic disorders. I spend my time at
UNM doing clinical research in schizophrenia, teaching residents, medical students and psychiatry
fellows and treating outpatients with chronic mental illness. I interact with faculty from the
Departments of Neuroscience and Psychology as well as scientists from the MIND Research
Network, an Albuquerque-based agency devoted to neuroimaging research. I particularly enjoy
mentoring residents and fellows interested in psychiatric research.
Selected Publications:

Bustillo J, Galloway M, Ghoddoussi F, Bolognani F, Perrone-Bizzozero N. Medial-frontal cortex
hypometabolism in chronic phencyclidine exposed rats assessed by high resolution magic angle spin
11.7T proton magnetic resonance spectroscopy, International J Neurochemstry, 2012 61(1):128-31.
Turner J, Chen H, Abbott C, Mathalon D, Allen E, Mayer A, Calhoun V, Bustillo J. Reliability of the
amplitude of low-frequency fluctuations in resting state in chronic schizophrenia, Psychiatry Res:
Neuroimaging 201 (2012), pp. 253-255
Bustillo J, Chen H, Gasparovic C, Mullins P, Caprihan A, Qualls C, Apfeldorf W, Lauriello J, Posse S.
Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4
Tesla. Biol Psychiatry. 2011 Jan 1;69(1):19-27.
Bustillo J, Rowland LM, Mullins P, Jung R, Chen H, Qualls C, Hammond R, Brooks WM, Lauriello J. 1H-
MRS at 4 tesla in minimally treated early schizophrenia. Mol Psychiatry. 2010 Jun;15(6):629-36
Carpenter WT, Bustillo J, Thaker GK, Van Os J, Krueger RF, Green MJ. The Psychoses: Cluster 3 of the
proposed metastructure for DSM-V and ICD-11. Psychological Medicine, 2009, 39 (12), 2025-2042
Bustillo J, Rowland L, Jung R, Brooks W, Qualls C, Hammond R, Hart B, Lauriello J. Proton Magnetic
Resonance Spectroscopy During Initial Treatment With Antipsychotic Medication in Schizophrenia.
Neuropsychopharmacology. 2008, 33, 2456-2466
Bustillo J, Barrow R, Paz R, Tang J, Seraji-Bozorgzad N, Moore G, Bolognani F, Lauriello J, Perrone-
Bizzozero N, Galloway M. Long term treatment of rats with haloperidol: lack of an effect on brain N-
acetyl aspartate levels, Neuropsychopharmacology, 2006, 31:751-756
Rowland L, Bustillo J, Mullins P, Jung R, Lenroot R, Landgraf E, Barrow R, Yeo R, Lauriello J, Brooks W.
The effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4.0T proton
magnetic resonance spectroscopy study, Am J Psychiatry, 2005 162: 394-396
Bustillo J, C Wolff, A Myers-y-Gutierrez, T Dettmer, T Cooper, A Allan, J Lauriello, C F Valenzuela.
Treatment of rats with antipsychotic drugs: lack of an effect on N acetyl-aspartate levels, Schizophrenia
Research, 2004; 66:31-39
Bustillo J, Lauriello J, Parker K, Hammond R, Rowland L, Bogenshutz M, Keith S. Treatment of weight
gain with fluoxetine in olanzapine treated schizophrenic outpatients, Neuropsychopharmacology, 2003;
Bustillo J, Lauriello J, Rowland L, Thomson L, Petropoulus H, Hammond R, Hart B, Brooks W. Longitudinal
follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia
patients with minimal previous medication exposure, Schizophrenia Research, 2002; 58:313-321
Bustillo J, Rowland L, Lauriello J, Petropoulus H, Hammond R, Hart B, Brooks W. Elevated choline
concentrations in the caudate nucleus in antipsychotic-naive schizophrenia, Am J Psychiatry, 2002;159:
Bustillo J, Lauriello J, Rowland L, Jung R, Petropoulus H, Hart B, Blanchard J, Keith S, Brooks W. Effects of
chronic haloperidol and clozapine treatments on frontal and caudate brain neurochemistry in
schizophrenia, Psychiatry Research Neuroimaging, 2001;107/3:135-149
Bustillo J, Lauriello J, Horan W, Keith SJ. The psychosocial treatment of schizophrenia: an update. Am J
Psychiatry 2001;158: 163-175
Bustillo J, Thaker G, Buchanan RW, Moran M, Kirkpatrick B, Carpenter WT. Visual information processing
impairments in deficit and nondeficit schizophrenia. Am J Psychiatry, 1997, 154:647-654
Bustillo J, Buchanan RW, Irish D, Breier A. Differential effect of clozapine on weight: a controlled study.
Am J Psychiatry, 1996, 153(6):817-819
Current Grants:
2009-2014. (Principal investigator: Juan Bustillo, MD). University of New Mexico School of Medicine, Department of Psychiatry. NIMH R01MH084898-01A1, “Brain Glutamate and Outcome in Schizophrenia”. 2011-2012. (Principal investigator: Juan Bustillo, MD). University of New Mexico Clinical and Translational Science Center, DHHS/NIH/NCRR 3 UL1 RR031977-02S2 “Gamma Oscillations and GABA Concentrations in Schizophrenia.” 2011-2012. (Principal investigator Administrative Supplement: Juan Bustillo, MD). University of New Mexico Clinical and Translational Science Center, DHHS/NIH/NCRR 3 UL1 RR031977-02S2 “Tracking medication-related changes in clinical state with resting state fMRI in Schizophrenia”. (Clinical Translational Science Center, PI: Richard Larson). 2008-2013. (Principal investigator UNM subaward: Juan Bustillo, MD). MIND Research Network. COBRE (P50) Grant: 1 P20 RR021938-01A1 “Neural Mechanisms of Schizophrenia: use of Multiple Neuroimaging Tools to Examine Dysfunction in Neural Integration”. (COBRE PI: Vince Calhoun).


Target cell availability and the successful suppression of hiv by hydroxyurea and didanosine

Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine Rob J. De Boer AIDS 1998, 12 :1567–1570 Keywords: Hydroxyurea, immunosuppression, target cell availability, resistance Introduction 72 weeks of ddI–HU treatment, three out of sixpatients had no detectable plasma virus, and that thereSurprisingly, immunosuppressive treatment canw

A novel approach to evaluating implementations of location-based software

A Novel Approach to Evaluating Implementations of Location-Based Software Daniel Herrscher, Steffen Maier, Jing Tian*, Kurt Rothermel University of Stuttgart, Institute of Parallel and Distributed Systems (IPVS)Universitätsstr. 38, D-70569 Stuttgart, Germany Keywords: performance analysis, network emulation, loca- resource requirements prohibit measurements in larger sce-tion-based

Copyright ©2018 Sedative Dosing Pdf